Table 2 Time Course of Study Measures
|  | Screening/ Eligibility (- 4 weeks) | Baseline (− 2 weeks) | Six consultations over an 8-week treatment period Weeks 0–8 | Post-Treatment 2 weeks Weeks 9–10 | Follow-Up 6-month Weeks 26–27 after end of treatment |
|---|---|---|---|---|---|
Screening Measures (Demographics, health, sleep disorders) | |||||
 Sociodemographics, medical and medications checklist, | X |  |  |  |  |
 Duke Sleep Interview | X |  |  |  |  |
 Mini-International Neuropsychiatric Interview, STOP-Bang, International Restless Legs Questionnaire, Epworth Sleepiness Scale | X |  |  |  |  |
 EEG (7 nights), actigraphy (7 days and nights) |  | X |  | X |  |
Outcome Measures (Sleep, insomnia, daytime symptoms, burden) | |||||
 Consensus sleep diary | X | X | X | X | X |
 Insomnia Severity Index | X | X | X | X | X |
 Patient Health Questionnaire-9 | X | X |  | X | X |
 Generalized Anxiety Disorder 7-item | X | X |  | X | X |
 Dysfunctional Beliefs and Attitudes about Sleep |  | X |  | X | X |
 Fatigue Severity Scale |  | X |  | X | X |
 Work and Social Impairment Scale |  | X |  | X | X |
 WHO-5 Well-Being Index |  | X |  | X | X |
 Cognitive Failures Questionnaire 2.0 |  | X |  | X |  |
Treatment-Related Measures | |||||
 Treatment acceptability and satisfaction |  | X |  | X | X |
 Treatment adherence scale |  |  | X |  |  |
 Ford Insomnia Response to Stress Test, Arousal Predisposition Scale, Pre-Sleep Arousal Scale | X |  | X | X |  |
 Adverse Events (Systematic Assessment for Treatment Emergent Events) |  | X | X | X |  |